Published • loading... • Updated
GLP-1 Makers Sued Over Rare Sudden Vision Loss
Thousands of patients say the companies failed to warn them about a rare eye stroke linked to sudden, sometimes permanent vision loss.
- Dozens of patients have filed Lawsuits against drugmakers Novo and Eli Lilly, alleging the companies failed to warn users about sudden vision loss from GLP-1s including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Non-Arteritic anterior ischaemic optic neuropathy, or NAION, is a rare condition that can lead to sudden and sometimes permanent vision loss due to lack of blood flow to the optic nerve.
- Research involving more than 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users compared to 19 in the comparison group; researchers also identified 93 patients with 'Other optic nerve disorders.'
- Similar Lawsuits against Eli Lilly are currently pending, with plaintiffs claiming the company failed to adequately warn patients of risks associated with their weight-loss and diabetes treatments.
- The American Academy of Ophthalmology encourages clinicians and patients to make 'informed choices' regarding GLP-1s, while noting that studies show modest risk but fewer patients experienced sight-threatening complications from diabetes.
Insights by Ground AI
Podcasts & Opinions
131 Articles
131 Articles
GLP-1 drugmakers are being sued by patients who suddenly lost their vision
Novo Nordisk and Eli Lilly are being sued by patients who say their GLP-1 weight-loss drugs have caused sudden vision loss. The lawsuits claim the patients should have been warned that vision loss was a rare side effect. The pharmaceutical companies say the lawsuits have no merit.
·Philadelphia, United States
Read Full Article
Coverage Details
Total News Sources131
Leaning Left19Leaning Right10Center81Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 17%
C 74%
Factuality
To view factuality data please Upgrade to Premium
